#Sustainability #India #Mumbai #Greenhouse Gases #Piramal Pharma

Piramal Pharma's Commitment to a Greener Future

Piramal Pharma Limited, a prominent player in the global pharmaceuticals landscape, has recently published its Sustainability Report for the fiscal year 2025-26, showcasing an inspiring journey towards a more sustainable future. Under the theme of "Advancing Innovation, Leveraging Sustainability," this report reveals critical advancements in environmental, social, and governance (ESG) priorities.

Key Achievements in Sustainability

In the latest report, Piramal Pharma highlights some remarkable statistics that underscore its commitment to sustainability:

• - Significant Emissions Reduction: The company has successfully reduced its Scope 1 and Scope 2 greenhouse gas emissions by 22.6% compared to the previous fiscal year, a remarkable achievement that marks a major milestone in its decarbonization efforts. This reduction not only demonstrates the company's proactive approach toward combating climate change but also aligns with the Science Based Targets initiative (SBTi), which further underscores its credibility in the global sustainability landscape.

• - Increase in Renewable Energy Usage: In another commendable move, Piramal Pharma has elevated its renewable energy utilization to 41% of total energy consumption across its operations. This transition to cleaner energy sources not only contributes to lower carbon emissions but also showcases the company's investment in sustainable technologies.

• - Water and Waste Management: The company recycled and reused 263,000 kiloliters of freshwater and successfully diverted 65% of its total waste for recycling. Such initiatives are crucial for maintaining resources in a world increasingly challenged by water scarcity and waste management issues.

Quality Assurance and Compliance

Piramal Pharma's dedication extends beyond environmental initiatives, prominently reflected in its quality assurance measures. During the reporting period, it completed 38 regulatory inspections, including three by the U.S. FDA, achieving zero Official Action Indicated (OAI) observations. This level of compliance speaks volumes about the company's stringent quality measures and commitment to operational excellence.

In addition to regulatory audits, the company conducted 209 customer audits, reinforcing its quality and compliance standards across its extensive global manufacturing network.

Digital Transformation

Recognizing the importance of innovation in operational efficiency, Piramal Pharma has also advanced its enterprise-wide digital transformation initiatives. Implementing tools such as Catalyst NxGen, SAP S/4HANA, and expanding digital quality systems have streamlined operations and enhanced overall productivity, aligning perfectly with its sustainability goals.

Governance and Community Impact

Governance remains a pivotal pillar for Piramal Pharma. The company maintained zero data breach incidents and corruption cases over the reporting year, showcasing its strong commitment to ethical practices and governance. Furthermore, it enhanced workforce diversity, with women representing 30% of the Board and 20.1% of the global staff, marking significant strides in diversity and inclusion.

In terms of community contribution, Piramal Pharma invested approximately ₹8.98 crore in CSR initiatives, positively impacting nearly 1.8 million individuals through healthcare and education programs. This reflects the company's focus on stakeholder engagement and community development.

Conclusion

Nandini Piramal, Chairperson of Piramal Pharma, summarizes the forward-thinking spirit of the organization, stating that sustainability should not merely be viewed as responsibility, but as a catalyst for innovation and resilience. With a strong emphasis on creating measurable impact, the future clearly looks promising for Piramal Pharma as it aspires to pioneer a new era of sustainable practices within the pharmaceutical industry.

The comprehensive Sustainability Report highlights Piramal Pharma's strategic framework, built around core pillars of Business Resilience, Quality Excellence, Responsible Operations, and Stakeholder Centricity. With over 50 time-bound sustainability targets, the company is well on its way to ensuring that ESG considerations remain a central element of long-term performance and stakeholder value creation.

For continued updates on Piramal Pharma’s sustainability journey, the complete report is available for public review, showcasing the company’s commitment to responsible business practices and sustainable growth.